Enzymatic Methods for the Site-Specific Radiolabeling of Targeting Proteins

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Jul 2

PMID 34201280

Citations 5

Authors

Cristina Bolzati

Barbara Spolaore

Affiliations

Soon will be listed here.

Abstract

Site-specific conjugation of proteins is currently required to produce homogenous derivatives for medicine applications. Proteins derivatized at specific positions of the polypeptide chain can actually show higher stability, superior pharmacokinetics, and activity in vivo, as compared with conjugates modified at heterogeneous sites. Moreover, they can be better characterized regarding the composition of the derivatization sites as well as the conformational and activity properties. To this aim, several site-specific derivatization approaches have been developed. Among these, enzymes are powerful tools that efficiently allow the generation of homogenous protein-drug conjugates under physiological conditions, thus preserving their native structure and activity. This review will summarize the progress made over the last decade on the use of enzymatic-based methodologies for the production of site-specific labeled immunoconjugates of interest for nuclear medicine. Enzymes used in this field, including microbial transglutaminase, sortase, galactosyltransferase, and lipoic acid ligase, will be overviewed and their recent applications in the radiopharmaceutical field will be described. Since nuclear medicine can benefit greatly from the production of homogenous derivatives, we hope that this review will aid the use of enzymes for the development of better radio-conjugates for diagnostic and therapeutic purposes.

Citing Articles

Site-specific bioconjugation and nuclear imaging.

Sebastiano J, Samuels Z, Kao W, Zeglis B Curr Opin Chem Biol. 2024; 81:102471.

PMID: 38833913 PMC: 11323144. DOI: 10.1016/j.cbpa.2024.102471.

Enzymatic Bioconjugation: A Perspective from the Pharmaceutical Industry.

Debon A, Siirola E, Snajdrova R JACS Au. 2023; 3(5):1267-1283.

PMID: 37234110 PMC: 10207132. DOI: 10.1021/jacsau.2c00617.

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: F-labeled rBC2LCN lectin.

Kuroda Y, Oda T, Shimomura O, Louphrasitthiphol P, Mathis B, Tateno H Cancer Sci. 2023; 114(8):3364-3373.

PMID: 37203465 PMC: 10394132. DOI: 10.1111/cas.15846.

A Review on the Current State and Future Perspectives of [Tc]Tc-Housed PSMA-i in Prostate Cancer.

Brunello S, Salvarese N, Carpanese D, Gobbi C, Melendez-Alafort L, Bolzati C Molecules. 2022; 27(9).

PMID: 35565970 PMC: 9099988. DOI: 10.3390/molecules27092617.

Bifunctional chelators for radiorhenium: past, present and future outlook.

Melis D, Burgoyne A, Ooms M, Gasser G RSC Med Chem. 2022; 13(3):217-245.

PMID: 35434629 PMC: 8942221. DOI: 10.1039/d1md00364j.

References

Adumeau P, Sharma S, Brent C, Zeglis B . Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans. Mol Imaging Biol. 2016; 18(1):1-17. PMC: 4722084. DOI: 10.1007/s11307-015-0919-4. View

Huang X, Aulabaugh A, Ding W, Kapoor B, Alksne L, Tabei K . Kinetic mechanism of Staphylococcus aureus sortase SrtA. Biochemistry. 2003; 42(38):11307-15. DOI: 10.1021/bi034391g. View

Tagami U, Shimba N, Nakamura M, Yokoyama K, Suzuki E, Hirokawa T . Substrate specificity of microbial transglutaminase as revealed by three-dimensional docking simulation and mutagenesis. Protein Eng Des Sel. 2009; 22(12):747-52. PMC: 2777024. DOI: 10.1093/protein/gzp061. View

Bouleau A, Lebon V, Truillet C . PET imaging of immune checkpoint proteins in oncology. Pharmacol Ther. 2020; 222:107786. DOI: 10.1016/j.pharmthera.2020.107786. View

Perry A, Ton-That H, Mazmanian S, Schneewind O . Anchoring of surface proteins to the cell wall of Staphylococcus aureus. III. Lipid II is an in vivo peptidoglycan substrate for sortase-catalyzed surface protein anchoring. J Biol Chem. 2002; 277(18):16241-8. DOI: 10.1074/jbc.M109194200. View

Strop P, Liu S, Dorywalska M, Delaria K, Dushin R, Tran T . Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013; 20(2):161-7. DOI: 10.1016/j.chembiol.2013.01.010. View

Mindt T, Jungi V, Wyss S, Friedli A, Pla G, Novak-Hofer I . Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. Bioconjug Chem. 2007; 19(1):271-8. DOI: 10.1021/bc700306n. View

Garousi J, Orlova A, Frejd F, Tolmachev V . Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. EJNMMI Radiopharm Chem. 2020; 5(1):16. PMC: 7311618. DOI: 10.1186/s41181-020-00094-w. View

Grimm J, Kiessling F, Pichler B . Molecular Imaging?. J Nucl Med. 2020; 61(10):1428-1434. DOI: 10.2967/jnumed.120.241984. View

10.

Ohtsuka T, Ota M, Nio N, Motoki M . Comparison of substrate specificities of transglutaminases using synthetic peptides as acyl donors. Biosci Biotechnol Biochem. 2001; 64(12):2608-13. DOI: 10.1271/bbb.64.2608. View

11.

Williams J, Kampmeier F, Badar A, Howland K, Cooper M, Mullen G . Optimal His-Tag Design for Efficient [Tc(CO)] and [Re(CO)] Labeling of Proteins for Molecular Imaging and Radionuclide Therapy by Analysis of Peptide Arrays. Bioconjug Chem. 2020; 32(7):1242-1254. PMC: 7611356. DOI: 10.1021/acs.bioconjchem.0c00561. View

12.

Policarpo R, Kang H, Liao X, Rabideau A, Simon M, Pentelute B . Flow-based enzymatic ligation by sortase A. Angew Chem Int Ed Engl. 2014; 53(35):9203-8. DOI: 10.1002/anie.201403582. View

13.

Houghton J, Zeglis B, Abdel-Atti D, Aggeler R, Sawada R, Agnew B . Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proc Natl Acad Sci U S A. 2015; 112(52):15850-5. PMC: 4702985. DOI: 10.1073/pnas.1506542112. View

14.

Ferrandiz C, Perez-Paya E, Braco L, Abad C . Gln5 selectively monodansylated substance P as a sensitive tool for interaction studies with membranes. Biochem Biophys Res Commun. 1994; 203(1):359-65. DOI: 10.1006/bbrc.1994.2190. View

15.

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

16.

Rashidian M, Ploegh H . Nanobodies as non-invasive imaging tools. Immunooncol Technol. 2022; 7:2-14. PMC: 9216400. DOI: 10.1016/j.iotech.2020.07.001. View

17.

Sato H, Hayashi E, Yamada N, Yatagai M, Takahara Y . Further studies on the site-specific protein modification by microbial transglutaminase. Bioconjug Chem. 2001; 12(5):701-10. DOI: 10.1021/bc000132h. View

18.

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F . An Overview of Targeted Alpha Therapy with Actinium and Bismuth. Curr Radiopharm. 2018; 11(3):200-208. PMC: 6237921. DOI: 10.2174/1874471011666180502104524. View

19.

Proft T . Sortase-mediated protein ligation: an emerging biotechnology tool for protein modification and immobilisation. Biotechnol Lett. 2009; 32(1):1-10. DOI: 10.1007/s10529-009-0116-0. View

20.

Marculescu C, Lakshminarayanan A, Gault J, Knight J, Folkes L, Spink T . Probing the limits of Q-tag bioconjugation of antibodies. Chem Commun (Camb). 2019; 55(76):11342-11345. PMC: 6788405. DOI: 10.1039/c9cc02303h. View